Evotec AG (NASDAQ:EVO – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $1.44 and last traded at $1.4350, with a volume of 19,766 shares traded. The stock had previously closed at $1.53.
Analyst Ratings Changes
EVO has been the subject of a number of recent research reports. Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. Finally, HC Wainwright dropped their price objective on shares of Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.00.
View Our Latest Stock Analysis on EVO
Evotec Stock Down 1.8%
Hedge Funds Weigh In On Evotec
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Apollon Wealth Management LLC purchased a new position in shares of Evotec during the 1st quarter valued at $28,000. SmartHarvest Portfolios LLC purchased a new stake in Evotec in the 1st quarter worth $44,000. WCM Investment Management LLC increased its stake in Evotec by 12.1% in the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after buying an additional 67,917 shares in the last quarter. Finally, Optiver Holding B.V. raised its holdings in Evotec by 598.4% during the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after acquiring an additional 242,973 shares during the period. 5.81% of the stock is currently owned by hedge funds and other institutional investors.
About Evotec
Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.
Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services.
Featured Articles
- Five stocks we like better than Evotec
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
